Going into Wednesday's Antimicrobial Drug Advisory Committee meeting, FDA reviewers appear comfortable with the clinical data to support approval of a second Gilead Sciences Inc. drug, Descovy (emtricitabine/tenofovir alafenamide), as a pre-exposure prophylaxis (PrEP) for HIV infections in men and transgender women who have sex with men (MSM/TGW).